|
1
|
Chen W, Zheng R, Zhang S, Zeng H, Xia C,
Zuo T, Yang Z, Zou X and He J: Cancer incidence and mortality in
China, 2013. Cancer Lett. 401:63–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fitzgerald JB, Schoeberl B, Nielsen UB and
Sorger PK: Systems biology and combination therapy in the quest for
clinical efficacy. Nat Chem Biol. 2:458–466. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schnipper LE, Davidson NE, Wollins DS,
Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR,
Langdon R, et al: American society of clinical oncology statement:
A conceptual framework to assess the value of cancer treatment
options. J Clin Oncol. 33:2563–2577. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sgambato D, Capuano A, Sullo MG, Miranda
A, Federico A and Romano M: Gut-brain axis in gastric mucosal
damage and protection. Curr Neuropharmacol. 14:959–966. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grubišić V, Verkhratsky A, Zorec R and
Parpura V: Enteric glia regulate gut motility in health and
disease. Brain Res Bull. Mar 29–2017.(Epub ahead of print). doi:
10.1016/j.brainresbull.2017.03.011. View Article : Google Scholar
|
|
7
|
Keightley PC, Koloski NA and Talley NJ:
Pathways in gut-brain communication: Evidence for distinct
gut-to-brain and brain-to-gut syndromes. Aust N Z J Psychiatry.
49:207–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sachlos E, Risueño RM, Laronde S,
Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn
A, Graham M, et al: Identification of drugs including a dopamine
antagonist that selectively target cancer stem cells. Cell.
149:1284–1297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mu J, Xu H, Yang Y, Huang W, Xiao J, Li M,
Tan Z, Ding Q, Zhang L, Lu J, et al: Thioridazine, an antipsychotic
drug, elicits potent antitumor effects in gastric cancer. Oncol
Rep. 31:2107–2114. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ke XY, Ng Lin VW, Gao SJ, Tong YW, Hedrick
JL and Yang YY: Co-delivery of thioridazine and doxorubicin using
polymeric micelles for targeting both cancer cells and cancer stem
cells. Biomaterials. 35:1096–1108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park MS, Dong SM, Kim BR, Seo SH, Kang S,
Lee EJ, Lee SH and Rho SB: Thioridazine inhibits angiogenesis and
tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian
cancer xenografts. Oncotarget. 5:4929–4934. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kang S, Dong SM, Kim BR, Park MS, Trink B,
Byun HJ and Rho SB: Thioridazine induces apoptosis by targeting the
PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells.
Apoptosis. 17:989–997. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen JS, Lin SY, Tso WL, Yeh GC, Lee WS,
Tseng H, Chen LC and Ho YS: Checkpoint kinase 1-mediated
phosphorylation of Cdc25C and bad proteins are involved in
antitumor effects of loratadine-induced G2/M phase cell-cycle
arrest and apoptosis. Mol Carcinog. 45:461–478. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin Y, Zhang H, Liang J, Li K, Zhu W, Fu
L, Wang F, Zheng X, Shi H, Wu S, et al: Identification and
characterization of alphavirus M1 as a selective oncolytic virus
targeting ZAP-defective human cancers. Proc Natl Acad Sci USA.
111:E4504–E4512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Strobl JS, Kirkwood KL, Lantz TK, Lewine
MA and Peterson VA III: Inhibition of human breast cancer cell
proliferation in tissue culture by the neuroleptic agents pimozide
and thioridazine. Cancer Res. 50:5399–5405. 1990.PubMed/NCBI
|
|
18
|
Gil-Ad I, Shtaif B, Levkovitz Y, Dayag M,
Zeldich E and Weizman A: Characterization of phenothiazine-induced
apoptosis in neuroblastoma and glioma cell lines: Clinical
relevance and possible application for brain-derived tumors. J Mol
Neurosci. 22:189–198. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhelev Z, Ohba H, Bakalova R, Hadjimitova
V, Ishikawa M, Shinohara Y and Baba Y: Phenothiazines suppress
proliferation and induce apoptosis in cultured leukemic cell
without any influence on the viability of normal lymphocytes.
Phenothiazines and leukemia. Cancer Chemother Pharmacol.
53:267–275. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Plati J, Bucur O and Khosravi-Far R:
Apoptotic cell signaling in cancer progression and therapy. Integr
Biol (Camb). 3:279–296. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Riedl SJ and Shi Y: Molecular mechanisms
of caspase regulation during apoptosis. Nat Rev Mol Cell Biol.
5:897–907. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
de Melo AC, Paulino E and Garces ÁH: A
review of mTOR pathway inhibitors in gynecologic cancer. Oxid Med
Cell Longev. 2017:48097512017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu L, Hofmann J and Jaffe RB:
Phosphatidylinositol 3-kinase mediates angiogenesis and vascular
permeability associated with ovarian carcinoma. Clin Cancer Res.
11:8208–8212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shi Y, Frankel A, Radvanyi LG, Penn LZ,
Miller RG and Mills GB: Rapamycin enhances apoptosis and increases
sensitivity to cisplatin in vitro. Cancer Res. 55:1982–1988.
1995.PubMed/NCBI
|
|
26
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
King D, Yeomanson D and Bryant HE: PI3King
the lock: Targeting the PI3K/Akt/mTOR pathway as a novel
therapeutic strategy in neuroblastoma. J Pediatr Hematol Oncol.
37:245–251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cardone MH, Roy N, Stennicke HR, Salvesen
GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of
cell death protease caspase-9 by phosphorylation. Science.
282:1318–1321. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo
P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rafalski VA and Brunet A: Energy
metabolism in adult neural stem cell fate. Prog Neurobiol.
93:182–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brown EJ, Albers MW, Shin TB, Ichikawa K,
Keith CT, Lane WS and Schreiber SL: A mammalian protein targeted by
G1-arresting rapamycin-receptor complex. Nature. 369:756–758. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sabatini DM, Erdjument-Bromage H, Lui M,
Tempst P and Snyder SH: RAFT1: A mammalian protein that binds to
FKBP12 in a rapamycin-dependent fashion and is homologous to yeast
TORs. Cell. 78:35–43. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wan X, Harkavy B, Shen N, Grohar P and
Helman LJ: Rapamycin induces feedback activation of Akt signaling
through an IGF-1R-dependent mechanism. Oncogene. 26:1932–1940.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dennis PB, Jaeschke A, Saitoh M, Fowler B,
Kozma SC and Thomas G: Mammalian TOR: A homeostatic ATP sensor.
Science. 294:1102–1105. 2001. View Article : Google Scholar : PubMed/NCBI
|
